In conclusion, we revealed a novel UBE2T/Mule/β-catenin signaling cascade that is involved in the regulation of liver CSCs, which provides an attractive potential therapeutic target for HCC. This evidence concerns the gene UBE2T and hepatocellular carcinoma.